Background. Methicillin-resistant Staphylococcus aureus (MRSA) is a common cause of complicated skin and skin-structure infection (cSSSI). Increasing antimicrobial resistance in cSSSI has led to a need for new safe and effective therapies. Ceftaroline was evaluated as treatment for cSSSI in 2 identical phase 3 clinical trials, the pooled analysis of which is presented here. The primary objective of each trial was to determine the noninferiority of the clinical cure rate achieved with ceftaroline monotherapy, compared with that achieved with vancomycin plus aztreonam combination therapy, in the clinically evaluable (CE) and modified intent-to-treat (MITT) patient populations.
these drugs can be limited by a narrow spectrum of activity, resistance, the need for monitoring of serum concentration, and/or adverse effects [11] [12] [13] .
Pathogenic streptococci are also showing signs of increasing resistance. Although S. pyogenes remains susceptible to most b-lactams, macrolide resistance has increased; recent global estimates range from 6.8% in the United States to 195% in China [14] [15] [16] [17] . In addition, 7.5% of isolates in Belgium were reported to be resistant to fluoroquinolones [18] . Non-group A and non-group B b-hemolytic streptococci have demonstrated resistance to erythromycin, fluoroquinolones, tetracycline, and clindamycin [19] . These factors suggest a need for additional safe and efficacious therapies with a spectrum consistent with commonly encountered cSSSI pathogens.
Ceftaroline fosamil (hereafter, ceftaroline) is a novel, broadspectrum cephalosporin prodrug, the active metabolite of which exhibits bactericidal activity against gram-positive organisms (including MRSA), vancomycin-intermediate S. aureus strains, and macrolide-resistant S. pyogenes, as well as potential gram-negative pathogens, including non-extended-spectrum b-lactamase (ESBL)-producing Klebsiella pneumoniae and Escherichia coli [20] [21] [22] [23] [24] . Ceftaroline is in development for treatment of hospitalized patients with cSSSI. A phase 2 trial initially investigated the efficacy and safety of ceftaroline in the treatment of cSSSI [25] .
This article describes the integrated findings of CANVAS 1 and CANVAS 2 (Ceftaroline versus Vancomycin in Skin and Skin-Structure Infection), 2 phase 3 clinical trials that compared ceftaroline monotherapy with vancomycin plus aztreonam combination therapy for the treatment of adults with cSSSI.
METHODS
Study design and treatment. CANVAS 1 (NCT00424190) and CANVAS 2 (NCT00423657) are phase 3, international, multicenter, randomized, double-blind, comparative efficacy and safety studies, with identical designs and protocols, of intravenous ceftaroline versus intravenous vancomycin plus aztreonam for 5-14 days in adults with cSSSI. The studies were designed to allow pooling of results for a larger database of pathogens and safety information. A total of 111 study centers in Europe, Latin America, and the United States participated.
Study participants were randomized to receive 600 mg of ceftaroline followed by normal saline placebo or 1 g of vancomycin followed by 1 g of aztreonam. All doses were masked within a yellow bag to maintain blinding. The ceftaroline dose was adjusted by unblinded pharmacy or study staff to 400 mg for patients with creatinine clearance 130 and р50 mL/min. The vancomycin dose was adjusted according to institutional guidelines or local prescribing practices. Treatments were administered intravenously in 250 mL of sodium chloride (0.9%) over 60 min every 12 h for 5-14 days. Therapy was deemed to be complete on the basis of investigator determination that all signs and symptoms of infection had resolved or improved such that no further antimicrobial therapy was necessary. If a gram-negative pathogen was neither identified nor suspected, the blinded investigator could decide to discontinue aztreonam (or placebo in the ceftaroline group). It was not mandatory for culture results to be obtained before randomization. Test-ofcure and late follow-up visits occurred 8-15 and 21-35 days, respectively, after the last dose of study drug.
Study populations. Inclusion and exclusion criteria are listed in Table 1 . The modified intent-to-treat (MITT) population included all randomized patients who received any treatment. The microbiological modified intent-to-treat (mMITT) population included MITT patients who met clinical disease criteria for cSSSI and had у1 bacterial pathogen isolated from blood or the cSSSI site at baseline. The clinically evaluable (CE) population included MITT patients who met clinical disease criteria for cSSSI, received a prespecified minimum amount of study drug, and for whom outcome information was available. The microbiologically evaluable (ME) population included CE patients with у1 bacterial pathogen isolated from blood or the cSSSI site at baseline. Patients were excluded from the ME population if baseline culture revealed monomicrobial Pseudomonas aeruginosa or anaerobic infection.
Efficacy assessments. At the test-of-cure visit, clinical cure was defined as total resolution of all signs and symptoms of the baseline infection or improvement such that no further antimicrobial therapy was necessary. Microbiological eradication was defined as absence of the baseline pathogen. Eradication was presumed if an adequate source specimen was not available for culture and the patient was assessed to have achieved clinical cure. At the late follow-up visit, relapse was noted if a patient considered to be clinically cured at the testof-cure visit exhibited a return of symptoms and/or signs of infection. Microbiological recurrence or reinfection was defined as isolation of a baseline or new pathogen from the original cSSSI site in patients who had clinical evidence of relapse.
Safety assessments. Safety assessments (MITT population) included physical examination, electrocardiogram, clinical chemistry and hematology parameters, coagulation tests, and reporting of adverse events (AEs) and serious AEs (SAEs). One patient randomized to ceftaroline received vancomycin plus aztreonam for the full course of therapy and thus was analyzed in the comparator group. Treatment-emergent AEs were defined as AEs with onset or worsening severity at or after the first dose of study drug through the test-of-cure visit (for all AEs) or the late followup visit (for SAEs only).
Statistical methods. Sample size was calculated using the Farrington-Manning method [26] . Assuming a point estimate for the primary outcome measure of a clinical cure rate of 85% in both treatment groups, a noninferiority margin of 10%, power Figure 1 . Disposition of patients in studies of ceftaroline versus vancomycin plus aztreonam (Vanco/Az) for the treatment of complicated skin and skinstructure infections. Eighteen patients were excluded from the modified intent-to-treat (MITT) population because they did not receive study drug; 334 patients were excluded from the microbiological MITT population because a baseline pathogen was not isolated, the minimal disease definition was not met, or they did not receive study drug; 194 patients were excluded from the clinically evaluable (CE) population, the most common reasons for which were indeterminate assessment at the test-of-cure visit ( ), breaking of the blind ( ), and receipt of a potentially effective concomitant n p 112 n p 20 antimicrobial (
). Patients from the CE population were included in the microbiologically evaluable (ME) population if they met the assessment n p 14 criteria, a baseline pathogen was isolated, and they did not have only anaerobic infection or monomicrobial Pseudomonas aeruginosa isolated from the infection site (482 patients were excluded from the ME population).
of 90%, and a 20% nonevaluable rate, a sample size of 690 patients (345 per treatment group) was required for each study.
The primary outcome measure in each study, as well as the integrated analysis, was the per-patient clinical cure rate at the test-of-cure visit in the CE and MITT populations (coprimary analysis). Secondary efficacy analyses included per-patient microbiological response and per-pathogen clinical and microbiological response at the test-of-cure visit and relapse and reinfection/recurrence rates at the late follow-up visit.
A 2-sided 95% confidence interval (CI) for the observed difference in the primary outcome measure between treatment groups was calculated using the Miettinen-Nurminen method [27] , stratified by study. Noninferiority was concluded if the lower limit of the 95% CI was above Ϫ10%. For per-patient microbiological response and clinical cure within subgroups of patients, 95% CIs were calculated using the same method and are provided for descriptive purposes.
RESULTS

Patient disposition and analysis populations.
Of the 1396 randomized patients in the ITT population, 1378 received study drug (for ceftaroline, ; for vancomycin plus aztreonam, n p 693 ) (Figure 1) . n p 685
Patient demographics and baseline medical characteristics. The patient population was predominantly white and male (Table 2), and 78.2% were hospitalized at study entry. The median patient age was 48 years; 18.1% and 7.5% were aged 65 and 75 years or older, respectively. Both treatment groups had similar demographic characteristics, type and site of cSSSI, and relevant medical or surgical history. Moderate renal impairment (creatinine clearance 130 and р50 mL/min) was present in 3.6% of patients. In 54.5% of cases, patients had у2 signs or symptoms (erythema, swelling, tenderness, or warmth) classified as severe; 36.3% had leukocytosis, and 29.9% were febrile. Bacteremia was present in 4.0% of patients. Infection types occurred at similar frequencies in the ceftaroline and vancomycin plus aztreonam groups, with cellulitis, major abscess, and infected wound accounting for the majority (Figure 2 ). The median infection area was 156 cm 2 for the ceftaroline group and 150 cm 2 for the vancomycin plus aztreonam group. All abscesses were required to contain loculated fluid and be surrounded by у2 cm of erythema. In addition, 188% had у1 dimension 15 cm. The mean treatment duration in the CE population was ∼8 days for both groups. A pathogen was isolated from 76.1% of patients; the most common pathogen isolated from the primary infection site was S. aureus, with MRSA accounting for 40% in the ceftaroline group and 34% in the vancomycin plus aztreonam group (Table 3) . Gram-negative potential pathogens were isolated from the primary infection site in 16.3% of patients; gram-negative bacteria alone were recovered from 5.9% of patients. Polymicrobial infections that included a gram-positive potential pathogen occurred in 20.6% of patients.
Clinical outcomes. In the integrated analysis, the efficacy of ceftaroline was similar to that of vancomycin plus aztreonam in the CE and MITT populations ( Table 4 ). The lower limit of the 95% CI was above Ϫ10%, which was the predefined requirement for noninferiority in each trial. Similarly, each of the 2 trials met the primary objective of noninferiority in the clinical cure rate for ceftaroline versus vancomycin plus aztreonam (95% CIs in CANVAS 1, Ϫ6.6 to 2.1 for CE and Ϫ4.1 to 6.2 for MITT; 95% CIs in CANVAS 2, Ϫ4.4 to 4.5 for CE and Ϫ5.8 to 5.0 for MITT). The efficacy of ceftaroline and of vancomycin plus aztreonam against polymicrobial and monomicrobial infections was similar (Table 4 ). Clinical cure rates by baseline pathogen are presented in Table 5 . Clinical cure rates in subgroups of patients (CE) were similar between treatment groups (Table 6 ). Infection type did not affect clinical cure rates between treatment groups. Of note, clinical cure was reported in 91.1% and 94.1% of patients with a major abscess in the ceftaroline and vancomycin plus aztreonam groups, respectively. When major abscesses were excluded from analysis (CE), the clinical cure rate remained similar both overall and between treatment groups (for ceftaroline, 91.9%; for vancomycin plus aztreonam, 92.1%). Clinical cure rates were similar between treatment groups for subgroups of patients with diabetes mellitus (for ceftaroline, 87.3%; for vancomycin plus aztreonam, 90.9%) or peripheral vascular disease (for ceftaroline, 88.9%; for vancomycin plus aztreonam, 89.3%).
Clinical cure rates among the 47 patients with bacteremia (CE) were 84.6% (22 of 26) for ceftaroline versus 100% (21 of 21) for vancomycin plus aztreonam (Table 6 ). Of note, more patients in the ceftaroline group than the comparator group experienced staphylococcal bacteremia (18 vs 9, respectively), whether caused by methicillin-susceptible S. aureus (11 vs 7) or MRSA (7 vs 2). The remaining bacteremias were predominantly caused by S. pyogenes (2 vs 3), gram-negative bacilli (2 vs 5), and other streptococci. Among patients with S. aureus bacteremia, the ceftaroline group had an 88.9% clinical cure rate. Similar cure rates were found among patients infected with MRSA. Four of the 26 patients in the ceftaroline-treated bacteremia group were classified as having experienced clinical NOTE. ME, microbiologically evaluable; mMITT, microbiological modified intent-to-treat; MRSA, methicillin-resistant S. aureus; MSSA, methicillin-susceptible S. aureus; NA, not applicable.
in the ceftaroline group, compared with 93.6% (88 of 94) of patients in the vancomycin plus aztreonam group (difference, Ϫ7.4%; 95% CI, Ϫ16.6% to 1.3%).
Safety and tolerability. Incidences of treatment-emergent AEs, regardless of relationship to study drug, were similar between study groups (Table 7) . Diarrhea occurred in 4.9% of patients in the ceftaroline group and in 3.8% of patients in the vancomycin plus aztreonam group (MITT population). C. difficile infection occurred in 2 patients in the ceftaroline group and in 1 patient in the vancomycin plus aztreonam group. These infections were successfully managed. AEs considered to be related to study drug in у3% of patients were pruritus, nausea, and diarrhea. Pruritus occurred more often with vancomycin plus aztreonam than with ceftaroline (8.2% vs 3.5%). The most common reason for premature discontinuation of study drug was possible allergic reactions (for ceftaroline, 1.9%; for vancomycin plus aztreonam, 2.9%).
An SAE occurred in 4.3% of patients in the ceftaroline group and in 4.1% of patients in the vancomycin plus aztreonam group. Important medical events related to ceftaroline therapy, such as neutropenia, thrombocytopenia, and liver failure, were not observed in these studies. Possible allergic reaction occurred in 2.0% and 4.1% of patients in the ceftaroline and vancomycin plus aztreonam groups, respectively. Three patients in the ceftaroline group died during the 2 studies. The causes of death were respiratory failure, neck cancer, and cardiopulmonary insufficiency; none of the deaths was assessed by an investigator as related to either study drug or the cSSSI.
As observed with cephalosporins, a higher incidence of Coombs test positivity was recorded in the ceftaroline group than in the comparator group; however, no laboratory or clinical manifestations of hemolytic anemia were identified. Fewer than 2% of patients in each group had a clinically significant electrocardiogram abnormality; the majority of these patients entered the study with an underlying condition that may have been associated with cardiac irregularities. No difference in abnormal physical findings or vital signs was identified between treatment groups. 
DISCUSSION
The data from this integrated analysis demonstrate that ceftaroline monotherapy is efficacious for the treatment of cSSSI, with a clinical cure rate comparable to that of vancomycin plus aztreonam. The cure rates consistently exceeded 93% in the ME population. The overall cure rate for ceftaroline-treated patients with staphylococcal infection was 93.1% (93.4% for patients with cSSSI caused by MRSA). The efficacy of ceftaroline monotherapy was consistently demonstrated in the relevant populations (CE, MITT, ME, and mMITT). In addition, clinical cure rates were similar between patients infected with single or multiple pathogens, across infection types (including cellulitis, major abscess, and infected wound), and between patients with common comorbidities, such as diabetes mellitus and peripheral vascular disease. The proportions of causative pathogens isolated in these studies are consistent with the broader epidemiologic picture of cSSSI. The majority of cSSSIs are caused by gram-positive pathogens [4] , as reflected in these studies. Additionally, 40% of S. aureus isolates in the ceftaroline group and 34% in the vancomycin plus aztreonam group were methicillin resistant, which is representative of the rate seen across countries with varying MRSA epidemiology [9, 10, [28] [29] [30] [31] [32] . As such, the CAN-VAS studies provide efficacy data in the context of the current endemicity of this important cSSSI pathogen.
The combination of vancomycin plus aztreonam demonstrated higher favorable microbiological response rates than did ceftaroline monotherapy against gram-negative infection. The efficacy of ceftaroline against non-ESBL-producing E. coli and K. pneumoniae infection was comparable to that of aztreonam; however, the efficacy of aztreonam against P. aeruginosa and Proteus mirabilis infection was better than that of ceftaroline. These results are not surprising, given in vitro data previously reported for ceftaroline [33] . Interestingly, despite the reported low in vitro activity against P. aeruginosa, ceftaroline therapy in the CANVAS trials demonstrated a high cure rate for this organism when found in combination with another pathogen. Given the difficulty of differentiating causative from colonizing pathogens in polymicrobial infections, it is not surprising that ceftaroline appears to be effective against infections from which ceftaroline-resistant organisms such as P. aeruginosa are isolated.
There was a trend toward a higher clinical cure rate among patients with bacteremia treated with vancomycin plus aztreonam; because of the small numbers of such cases (with greater numbers and more staphylococci in the ceftaroline group), this observation is of unknown significance. Of note, sterilization of blood cultures was achieved during continued therapy in the 3 ceftaroline-treated patients with staphylococcal or streptococcal bacteremia who were assessed as experiencing clinical failure. This finding confirms the designation of clinical failure as a result of reasons other than a lack of microbiological efficacy.
Safety and tolerability of new antibiotics are of primary concern, especially in light of the limitations demonstrated by several currently available anti-MRSA agents. Data from 11300 patients in this analysis demonstrated that ceftaroline monotherapy was generally safe and well tolerated, consistent with the safety profile of the cephalosporin class. The incidence of treatment-emergent AEs was similar between treatment groups. No cardiac, hepatic, or renal toxicity signal was identified.
The inclusion of a significant number of cutaneous abscesses in cSSSI trials is controversial. It is recognized that many small, uncomplicated cutaneous abscesses can be treated with incision and drainage alone [34] . Antimicrobial therapy is recommended when abscesses are large, surrounded by extensive cellulitis, or accompanied by systemic symptoms [35] . By design, abscesses in these studies fulfilled several or all of these criteria. In addition, the CANVAS trials were similar to other recent studies of antimicrobial treatment of cSSSI [36, 37] , which also included a high proportion of abscesses. Most importantly, significant efficacy was maintained in both groups when abscesses were excluded from analyses, with ceftaroline being comparable to vancomycin plus aztreonam.
Potential limitations of these analyses include small numbers of black, Asian, and elderly (175 years old) patients and the exclusion of patients !18 years old; these are typical of registrational trials of new antimicrobials. Future studies involving such important populations as patients with diabetic foot infection will be needed to supplement the current understanding of the safety and efficacy profile of ceftaroline.
In conclusion, ceftaroline administered intravenously to adults at a dosage of 600 mg every 12 h for 5-14 days was efficacious and well tolerated for the treatment of cSSSI. In light of these analyses, ceftaroline has the potential to provide a monotherapy alternative for the treatment of cSSSI.
